Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Shares Acquired by Geode Capital Management LLC

Geode Capital Management LLC increased its holdings in Eton Pharmaceuticals, Inc. (NASDAQ:ETON) by 13.5% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 272,696 shares of the company’s stock after buying an additional 32,365 shares during the quarter. Geode Capital Management LLC’s holdings in Eton Pharmaceuticals were worth $1,637,000 at the end of the most recent reporting period.

Several other large investors have also recently added to or reduced their stakes in the business. Point72 Asia Singapore Pte. Ltd. acquired a new position in Eton Pharmaceuticals during the 3rd quarter worth $54,000. Jane Street Group LLC acquired a new stake in Eton Pharmaceuticals in the third quarter worth about $90,000. Connor Clark & Lunn Investment Management Ltd. grew its position in Eton Pharmaceuticals by 86.6% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 65,014 shares of the company’s stock valued at $390,000 after buying an additional 30,167 shares in the last quarter. Renaissance Technologies LLC increased its stake in Eton Pharmaceuticals by 63.8% during the 2nd quarter. Renaissance Technologies LLC now owns 106,500 shares of the company’s stock valued at $350,000 after buying an additional 41,469 shares during the period. Finally, Stonepine Capital Management LLC bought a new stake in shares of Eton Pharmaceuticals during the 2nd quarter worth about $362,000. 27.86% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several research analysts have recently issued reports on ETON shares. HC Wainwright increased their price objective on shares of Eton Pharmaceuticals from $15.00 to $17.00 and gave the company a “buy” rating in a report on Monday. Craig Hallum increased their price target on Eton Pharmaceuticals from $15.00 to $18.00 and gave the company a “buy” rating in a research note on Wednesday.

Eton Pharmaceuticals Trading Up 0.2 %

NASDAQ:ETON opened at $12.01 on Thursday. The company has a 50-day moving average of $11.57 and a 200-day moving average of $7.32. The firm has a market cap of $312.87 million, a price-to-earnings ratio of -54.59 and a beta of 1.38. Eton Pharmaceuticals, Inc. has a twelve month low of $3.03 and a twelve month high of $15.00.

About Eton Pharmaceuticals

Eton Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1.